Fairvalue-Calculator Fairvalue-Calculator

Imeik Technology Development Co (300896) Fair Value & Analysis

Healthcare · CN · Market cap 27.9B CNY

Price¥92.17
Fair Value¥77.95
Upside-15.4%
Quality85/100
Evidence: Medium Range ¥59.47 – ¥96.43

Analysis

Imeik Technology Development Co (300896) currently trades at ¥92.17, while our model-based Fair Value estimate is ¥77.95 — implying the stock looks roughly 15.4% overvalued today. We read business quality at 85/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Imeik Technology Development Co.,Ltd. engages in the research and development, and transformation of biomedical materials and biopharmaceutical products in China. The company offers aesthetic medicine products, such as cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere; poly facial implant thread; medical sodium hyaluronate-hydroxypropyl methylcellulose gel; sodium hyaluronate composite solution for injection; modified sodium hyaluronate gel for injection; medical PVA gel ball-sodium hyaluronate-hydroxypropyl methylcellulose gel; and skin care products. It serves medical aesthetic institutions. The company was incorporated in 2004 and is headquartered in Beijing, China.

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -55% EssilorLuxottica Société anonyme (ESLOF) -44% HOYA Corporation (HOCPY) -42% Medline Inc (MDLN) -13% Becton, Dickinson and Company (BDX) -28% Alcon Inc (ALC) -33%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.